Tina M. Albertson

Insider

First SEC filing: March 29, 2022 · Latest: March 29, 2022

On this page

Insider at

0 buys (P) 0 sells (S) Net: $0 + 1 non-open-market transaction below last 12 months, based on the transactions shown below

Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted

No open-market trades on record; showing all filings.

Date	Ticker	Code	Shares	Price	Value	Owned after	Δ own	A/D	vs now
Feb. 24, 2023	LYEL	A	700,000	—	—	700,000 Direct	—	Acquired	(price as of 2026-08-21)

P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding

Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.

Options, RSUs and convertible securities reported on Form 4 Table II.

Date	Ticker	Security	Underlying	Exercise price	Expiration	Shares	A/D
Feb. 24, 2023	LYEL	Option (right to buy)	Common Stock (700,000)	$2.13	Feb. 23, 2033	700,000	Acquired

Exercise/conversion price is blank when not applicable (e.g. RSUs).

Securities held when first becoming an insider, per SEC Form 3.

Date	Ticker	Security	Shares	Ownership
March 29, 2022	LYEL	Option (right to buy)→ Common Stock (500,000)	500,000	Direct
March 29, 2022	LYEL	Option (right to buy)→ Common Stock (400,000)	400,000	Direct
March 29, 2022	LYEL	Option (right to buy)→ Common Stock (600,000)	600,000	Direct

Matched by name from proxy statements (DEF 14A) — verify against the filing.

M.D., Ph.D.Former Chief Medical Officer and Head of Development(14)(15)

Fiscal year	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension change	Other	Total
2023	$473,444	$42,097	—	$1,149,820	—	—	$726,042	$2,391,403

Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.